Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

NCT06685289 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Biliary Malignant Tumors

Interventions

DRUG: Donafenib
DRUG: capecitabine

Sponsor

The First Affiliated Hospital with Nanjing Medical University